DigiMed Bayern

Your contact

Dr. Stefan Mitterreiter

Project Manager DigiMed Bayern & AI4Biotech

Dr. Tim-Henrik Bruun

Technology & Data Solutions Lead, Digital R&D

DigiMed Bayern for the Medicine of the Future

Homepage of the Project: www.digimed-bayern.de

P4 medicine (predictive, preventive, personalized, participatory) is one of the world's most promising developments for improved, holistic and efficient health care. 

DigiMed Bayern's goal is to guide Bavaria into this medicine of the future with a flagship project. The flagship P4-medicine project DigiMed Bayern has been funded by the Bavarian Ministry of Health, Care and Prevention with around 27 million euros from 2018 to 2027. 

DigiMed Bayern combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with state-of-the-art multi-dimensional molecular characterization (-omics technologies) of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be fundamentally designed and implemented. 
 

Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.

Superior goals of DigiMed Bayern

1. Using the example of atherosclerosis, a first analysis of comprehensive data sets in the sense of digital medicine of the future is carried out. All those involved in the health care system in Bavaria should benefit directly: the prediction for coronary heart disease (CHD) and stroke should be made more accurate in the short term and preventive treatment should be improved. In the medium to long term improvements in diagnosis and therapy are pursued. The population-wide identification of familial hypercholesterinemia as an exemplary risk factor for atherosclerosis should be sustainably improved.
2. The technical, legal and social possibilities and limitations of P4 medicine are recorded, promoted and documented by means of concrete implementation. This includes a proactive multi-directional information exchange with all those involved in health, with a focus on systemic development.
3. Resulting insights and structures should be expandable in the health system, in research and in the economy and be transferable to other diseases. In particular, an exemplary and transferable integrated digital infrastructure should be created.
4. Bavaria as a location for P4 medicine should be substantially developed, including international perception and internationally networking.

Planned duration:
October 2018 to November 2027

Scientific Directorate:   
German Heart Centre Munich

Managing Directorate:
BioM Biotech Cluster Development GmbH

 

Initially involved Institutions